AstraZeneca Signs Two Deals to Advance its Virtual Neuroscience R&D Strategy
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 25 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1783 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca’s neuroscience Innovative Medicines Unit (iMed) has acquired a portfolio of preclinical and clinical-stage neuroscience candidates that target the enzyme farnesyltransferase and modulate autophagy from Link Medicine...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS